Skip to main content
. 2017 Nov 1;37(44):10671–10678. doi: 10.1523/JNEUROSCI.1971-17.2017

Figure 4.

Figure 4.

Within-scan challenges and pretreatment with the 5-HT1BR antagonist GR127935. A, Average changes in CBV upon administration of GR127935 (200 μg/kg) performed in two different animals. B, Representative time-activity curve of [11C]AZ10419369 with a GR127935 challenge (200 μg/kg). C, Changes in CBV of upon administrating GR127035 (500 μg/kg) before the injection of radioligand and a subsequent within-scan challenge of AZ10419369 (5.0 μg/kg). D, Time-activity curve of [11C]AZ10419369 after GR127935 pretreatment (500 μg/kg) and with a within-scan challenge of AZ10419369.